Clinical Trial Update: Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 trial of lenalidomide in pediatric patients with relapsed or refractory myelodysplastic syndromes and solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Solid Tumors

Drugs mentioned

• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED